The invention relates to novel amidines and quanidines, the production and use thereof and the use thereof as trypsine-type serine protease competitive inhibitors, especially thrombine and compliment proteases CIs and C1r. The invention also relates to pharmaceutical compositions which contain said compounds as active ingredients, in addition to the use of the compounds as thrombine inhibitors, anticoagulants, compliment inhibitors and anti-inflammatory agents. The novel compositions are characterised by the linkage of a serine protease inhibitor having amidine or guanidine functions with an alkyl radical having two or more hydroxyl functions, whereby said alkyl radical is derived from sugar derivates. Several sugar structural components or components derived from sugar can therefore be linked to each other. Said principle of linking sugar derivates enables oral active compounds to be obtained.
本发明涉及新型的胺基
脲和
脲,其制备和使用以及作为胰
蛋白酶类
丝氨酸蛋白酶竞争性
抑制剂,特别是凝血酶和补体
蛋白酶CI和C1r的用途。本发明还涉及含有上述化合物作为活性成分的药物组合物,以及将这些化合物用作凝血酶
抑制剂、抗凝剂、补体
抑制剂和抗炎剂。这些新型组合物的特点是将带有胺基
脲或
脲功能的
丝氨酸蛋白酶抑制剂与具有两个或两个以上羟基功能的烷基基团连接起来,其中所述烷基基团来自糖衍
生物。因此,几种糖结构成分或来自糖的成分可以相互连接。这种将糖衍
生物连接起来的原理使得可以获得口服活性化合物。